APG-2449(CAT: I040691) is a potent, orally bioavailable, multi-targeted tyrosine kinase inhibitor that selectively targets ALK, ROS1, and FAK kinases. It is under investigation for the treatment of various cancers, particularly non-small cell lung cancer (NSCLC) with ALK or ROS1 rearrangements, and tumors exhibiting FAK overexpression. APG-2449 inhibits oncogenic signaling pathways involved in tumor proliferation, survival, and metastasis. It has demonstrated efficacy in preclinical cancer models, including those resistant to first-generation ALK inhibitors. By concurrently inhibiting FAK, APG-2449 may also overcome resistance mechanisms and modulate the tumor microenvironment, supporting its potential as a next-generation therapy in targeted oncology.